RxDoctor Payments Data

Babatunde Shittu, NP

Psychiatric/Mental Health · Grand Prairie, TXNPI 1497385645

Payments from drug & device makers

$782in general payments, 2019–2025

Across 50 payments — averaging $15.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$264
  • AbbVie$206
  • Neurocrine Biosciences, Inc.$64
  • Takeda Pharmaceuticals U.S.A., Inc.$56
  • Sunovion Pharmaceuticals Inc.$53
  • Vanda Pharmaceuticals Inc.$30
  • plus $111 from 7 others

What the payments were for

  • Food & beverage$782100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$782 in reported general payments places this provider in the 55th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$12,687
Medicare patients
45
Services billed
165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate43$118,512
VraylarCariprazine Hcl24$33,964
CaplytaLumateperone Tosylate12$19,693
Aripiprazole190$16,321
TrintellixVortioxetine Hydrobromide20$9,595
Quetiapine Fumarate266$6,199
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl29$6,015
Divalproex Sodium ErDivalproex Sodium49$5,876
Trazodone Hcl414$4,144
Divalproex Sodium110$3,771
Oxcarbazepine58$3,378
Bupropion XlBupropion Hcl204$3,110
Doxepin Hcl98$3,051
Clonazepam218$2,885
Olanzapine118$2,843

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$19$118,51243 claims
AbbVieVraylar$206$33,96424 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$264$19,69312 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$56$9,59520 claims
Almatica Pharma LLCSertraline Hcl$19$53170 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Grand Prairie

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →